Bill Tan

Dr. Bill Tan joined Adverum Biotechnologies in March 2021 and leads the strategic planning and implementation of Adverum’s clinical development programs. This includes overseeing Adverum’s integrated global clinical development plans from a strategic, operational, and technical perspective within the clinical operations team. Previously, Dr. Tan worked with 89bio where he served as a senior consultant for clinical operations and was responsible for strategic and operational oversight, management, execution, and timely delivery of their pipeline for non-alcoholic steatohepatitis (NASH) and treatment of severe hypertriglyceridemia. Prior to 89bio, Dr. Tan held numerous clinical development and operations roles, including senior consultant for clinical operations at Mirum Pharmaceuticals, during which he lead the operationalization of trials for volixibat in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis. Before Mirum, Dr. Tan was director of clinical development at Allergan (subsequently acquired by AbbVie) where he initiated and oversaw more than 450 clinical trial sites globally for the pivotal Phase 3 NASH trial. Dr. Tan has also held numerous roles of increasing responsibility including director of medical affairs at Dermira (subsequently acquired by Eli Lilly); director of medical affairs at Anacor (subsequently acquired by Pfizer); director of medical information at Onyx Pharmaceuticals (acquired by Amgen); and consultant for medical information and health economics at Gilead Sciences. He has a broad background in drug development with strong leadership to motivate, manage, and empower global R&D teams and has broad therapeutic experience in liver, cardiovascular, endocrinology, dermatology, infectious disease and oncology. Dr. Tan earned a Doctor of Pharmacy from the University of California, San Francisco, and holds a Bachelor of Science in Biochemistry from the University of California, Los Angeles.